Sonographic patterns of renal lymphoma in B-mode imaging and in contrast-enhanced ultrasound (CEUS)—A retrospective evaluation

Trenker, Corinna; Neeße, Albrecht; Görg, Christian

doi:10.1016/j.ejrad.2014.12.027

Cited by 16 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Color Doppler imaging can be used to assess the patency of the peripancreatic vasculature. Pilot studies of contrast-enhanced US demonstrated hypoechoic enhancement in renal, liver, and splenic lymphomas, which logically may also apply to pancreatic lymphoma, although larger confirmative studies are needed (68,69).…”

Section: Lymphomamentioning

confidence: 94%

Nonepithelial Neoplasms of the Pancreas, Part 2: Malignant Tumors and Tumors of Uncertain Malignant PotentialFrom the Radiologic Pathology Archives

Manning

Paal²,

Srivastava

et al. 2018

RadioGraphics

View full text Add to dashboard Cite

Almost all neoplasms of the pancreas are derived from pancreatic epithelial components, including the most common pancreatic mass, primary pancreatic ductal adenocarcinoma (PDAC). Nonepithelial neoplasms comprise only 1%-2% of all pancreatic neoplasms. Although some may arise directly from intrapancreatic elements, many originate from mesenchymal, hematopoietic, or neural elements in the retroperitoneal peripancreatic space and grow into the pancreas. Once these tumors reach a certain size, it can be challenging to identify their origin. Because these manifest at imaging as intrapancreatic masses, awareness of the existence and characteristic features of these nonepithelial neoplasms is crucial for the practicing radiologist in differentiating these tumors from primary epithelial pancreatic tumors, an important distinction given the vastly different management and prognosis. In part 1 of this article, the authors reviewed benign nonepithelial neoplasms of the pancreas. This article focuses on malignant nonepithelial neoplasms and those of uncertain malignant potential that can be seen in the pancreas. The most common malignant or potentially malignant nonepithelial pancreatic tumors are of mesenchymal origin and include soft-tissue sarcomas, solitary fibrous tumor, and inflammatory myofibroblastic tumor. These tumors commonly manifest as large heterogeneous masses, often containing areas of necrosis and hemorrhage. The clinical features associated with these tumors and the imaging characteristics including enhancement patterns and the presence of fat or calcification help distinguish these tumors from PDAC. Hematopoietic tumors, including lymphoma and extramedullary plasmacytoma, can manifest as isolated pancreatic involvement or secondarily involve the pancreas as widespread disease. Hyperenhancing paragangliomas or hypervascular metastatic disease can mimic primary pancreatic neuroendocrine tumors or vascular anomalies.

show abstract

Section: Lymphomamentioning

confidence: 94%

Nonepithelial Neoplasms of the Pancreas, Part 2: Malignant Tumors and Tumors of Uncertain Malignant PotentialFrom the Radiologic Pathology Archives

Manning

Paal²,

Srivastava

et al. 2018

RadioGraphics

View full text Add to dashboard Cite

show abstract

“…On CEUS exam, both types of metastatic lesions have similar behaviour (hypo or isoenhancement in early corticamedulary phase followed by an early wash-out) [30,34,35]. Ignee A et al [30] suggested that non-renal tumour metastases in CEUS exam are typically hypovascular in more than 80% of cases [30].…”

Section: Differential Diagnosis Between Rccs and Other Renal Malignancymentioning

confidence: 99%

“…As RCCs may display the same pattern , CEUS cannot be used to differentiate RCCs and other renal malignancy [30,34,35] .…”

Section: Differential Diagnosis Between Rccs and Other Renal Malignancymentioning

confidence: 99%

Contrast enhanced ultrasound of renal masses. A reappraisal of EFSUMB recommendations and possible emerging applications.

et al. 2015

View full text Add to dashboard Cite

The main imagistic method for characterization of renal lesions is contrast enhanced computed tomography (CECT). Disadvantages of CECT are a contrast-induced nephropathy in patients with renal impairment, allergic reactions and high costs. Contrast-enhanced ultrasound (CEUS) evaluation of hepatic and non-hepatic lesions is a relatively new, but increasingly utilised, diagnostic method. In 2011 the European Federation of Societies of Ultrasound in Medicine and Biology (EFSUMB) updated the Guidelines and Recommendations on the Clinical Practice of CEUS and included in the recommendation the renal pathology. However, there are several possible new indications that have not been discussed (pyelocaliceal masses and renal vein thrombosis) and several issues that remain controversial such as the differentiation of benign and malignant tumours or the differentiation of lymphoma and metastasis.This study aims to review literature data, as well as reveal the latest findings in the field of renal CEUS.

show abstract

“…With the application of contrast agent, diagnostic level of ultrasound is improved. CEUS can objectively display the shape, size and number of tumors, and at the same time, it can reflect the characteristics of blood flow inside the tumor ( 18 ), which is similar to the function of enhanced CT. CEUS can be an alternative to enhanced CT in the diagnosis of liver cancer, and can provide a reliable basis for treatment of liver cancer.…”

Section: Discussionmentioning

confidence: 99%

Application of contrast‑enhanced ultrasound and enhanced CT in diagnosis of liver cancer and evaluation of radiofrequency ablation

Kong

Yue

Kong³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

This study investigated the application effect of contrast-enhanced ultrasound (CEUS) and enhanced CT in diagnosis of liver cancer and response evaluation of radiofrequency ablation (RFA). A total of 60 patients with liver cancer were selected in Dongying People's Hospital from April 2016 to May 2017. All patients were subjected to CEUS and enhanced CT. With pathological examination as the gold standard, diagnostic consistency of the two methods was compared. After RFA, patients were subjected to CEUS and enhanced CT to assess the efficacy, and the consistency was compared. There was no significant difference in diagnostic accuracy between CEUS and CT (p>0.05). Area under the ROC curve of CEUS was 0.896, with a sensitivity of 91.2% and a specificity of 88.7%. The area under the ROC curve for enhanced CT diagnosis was 0.907, with a sensitivity of 91.8% and a specificity of 89.7%. No significant difference in the maximal cross sectional area of lesions was found between CEUS and enhanced CT, and there was no significant difference in evaluation of therapeutic efficiency between the methods (p>0.05) before and 1 and 3 months after treatment. Bland-Altman test showed that there was a strong consistency between CEUS and enhanced CT in the measured maximum cross-sectional area of lesions at 1 and 3 months after treatment. Linear regression analysis showed that maximum section cross-sectional area measured by CEUS was significantly correlated with that detected by enhanced CT (r2=0.617). The results suggested that diagnostic efficiency of CEUS was similar to that of enhanced CT, and both showed high sensitivity and specificity. Two methods showed high consistency in evaluating the curative effect of RFA. CEUS can achieve real-time observation of focal blood flow perfusion, and was more economically affordable and convenient.

show abstract

Sonographic patterns of renal lymphoma in B-mode imaging and in contrast-enhanced ultrasound (CEUS)—A retrospective evaluation

Cited by 16 publications

References 15 publications

Nonepithelial Neoplasms of the Pancreas, Part 2: Malignant Tumors and Tumors of Uncertain Malignant PotentialFrom the Radiologic Pathology Archives

Nonepithelial Neoplasms of the Pancreas, Part 2: Malignant Tumors and Tumors of Uncertain Malignant PotentialFrom the Radiologic Pathology Archives

Contrast enhanced ultrasound of renal masses. A reappraisal of EFSUMB recommendations and possible emerging applications.

Application of contrast‑enhanced ultrasound and enhanced CT in diagnosis of liver cancer and evaluation of radiofrequency ablation

Contact Info

Product

Resources

About